Press "esc" to clear
Go to Advanced Search

Showing results

110 of 1019
Cortes.jpg
  • Embargo expired:
    16-Jun-2018 2:30 AM EDT

Article ID: 696175

Phase III study shows quizartinib prolongs overall survival for patients with deadly type of relapsed or refractory AML

University of Texas M. D. Anderson Cancer Center

A study led by The University of Texas MD Anderson Cancer Center revealed that the investigational drug quizartinib prolonged overall survival for patients with a deadly form of acute myeloid leukemia (AML) linked to a genetic mutation called FMS-like internal tandem duplications (FLT3-ITD).

Released:
15-Jun-2018 10:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
148380_Sharma_P11.jpg

Article ID: 696198

Researchers Find Combination Can Enhance Ipilimumab Immunotherapy

University of Texas M. D. Anderson Cancer Center

Using a targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors, researchers at The University of Texas MD Anderson Cancer Center report today in the Journal of Clinical Investigation.

Released:
15-Jun-2018 4:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
fathersdayblog_image.jpg

Article ID: 696157

Checking in (and Checking up) on Dad this Father’s Day

Rutgers Cancer Institute of New Jersey

Instead of another tie or tools, give the gift of good health this Father’s Day. As Rutgers Cancer Institute of New Jersey experts note, it’s as simple as encouraging regular health screenings to protect against cancer.

Released:
14-Jun-2018 4:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
Rosenberg_Aaron.jpg

Article ID: 696030

Stem Cell Transplants Extend Life for Multiple Myeloma Patients

UC Davis Comprehensive Cancer Center

Researchers at UC Davis have confirmed that autologous hematopoietic stem cell transplant improves survival for people suffering from multiple myeloma, yet many potentially eligible patients never undergo the procedure.

Released:
12-Jun-2018 2:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
PeterMeinke.jpg

Article ID: 696018

Distinguished Chemist Selected to Lead the Tri-Institutional Therapeutics Discovery Institute

Memorial Sloan Kettering Cancer Center

Peter T. Meinke, PhD, an accomplished chemist with more than 30 years of industry and academic experience, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute.

Released:
12-Jun-2018 12:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 695986

Newly-Approved Therapy Provides Improved Quality of Life for Patients with Advanced Metastatic Midgut Neuroendocrine Tumors

Moffitt Cancer Center

Midgut neuroendocrine tumors are a rare type of cancer that develops in the small intestine and colon. Roughly 12,000 people are diagnosed with this disease each year. In January, the United Stated Food and Drug Administration approved Lutathera, a first-of-its-kind peptide receptor radionuclide therapy. The injection consists of a somatostatin analog combined with a radioactive isotope that directly targets neuroendocrine tumor cells.

Released:
12-Jun-2018 9:25 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
IntegrativeTherapiesforBreastCancer06-11-18.jpg

Article ID: 695972

Mozart, Meditation and a Yoga Mat: Oncologists Welcome Certain Integrative Therapies Into the Breast Cancer Treatment Mix

Fred Hutchinson Cancer Research Center

A breast cancer patient dealing with anxiety, depression or mood swings could soon be encouraged by her oncologist to learn meditation techniques, join a yoga class or put music to therapeutic use. Today, the American Society of Clinical Oncology (ASCO), published its endorsement of integrative therapy guidelines recently established by the Society for Integrative Oncology (SIO).

Released:
11-Jun-2018 6:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
LaurenByers.jpg
  • Embargo expired:
    11-Jun-2018 4:00 PM EDT

Article ID: 695948

PARP Inhibitor Improves Overall Response Rates in Small Cell Lung Cancer Patients

University of Texas M. D. Anderson Cancer Center

In a randomized, Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved overall response rates (ORR) in patients with small cell lung cancer (SCLC). Researchers also identified a select group of patients – those whose tumors expressed SLFN11— who also saw a progression-free survival (PFS) and overall survival (OS) benefit, suggesting a promising biomarker for the PARP-inhibitor sensitivity in SCLC.

Released:
11-Jun-2018 3:20 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
Marszalek.jpg
  • Embargo expired:
    11-Jun-2018 11:00 AM EDT

Article ID: 695886

MD Anderson Therapeutics Discovery team identifies and advances a drug that targets metabolic vulnerability and impairs cancer cell growth and survival

University of Texas M. D. Anderson Cancer Center

A drug discovered and advanced by The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS) and the Center for Co-Clinical Trials (CCCT) inhibits a vital metabolic process required for cancer cells’ growth and survival.

Released:
8-Jun-2018 6:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
180608-NR-mugs-02.jpg

Article ID: 695822

Head of Allen Institute and Top Lyft Executive Join Fred Hutch Board of Trustees

Fred Hutchinson Cancer Research Center

Fred Hutchinson Cancer Research Center announced the election of a new board of trustees chair, a new vice chair and two new members. Each brings additional expertise in finance, technology, bioscience and data science as the Hutch accelerates efforts to develop cures for cancer and other diseases.

Released:
8-Jun-2018 11:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Showing results

110 of 1019





Chat now!